"Cyclophosphamide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
| Descriptor ID |
D003520
|
| MeSH Number(s) |
D02.455.526.728.650.730.243 D02.705.672.500.243
|
| Concept/Terms |
Cyclophosphamide- Cyclophosphamide
- Cytophosphane
- Cyclophosphamide Monohydrate
- Monohydrate, Cyclophosphamide
- Cyclophosphane
|
Below are MeSH descriptors whose meaning is more general than "Cyclophosphamide".
Below are MeSH descriptors whose meaning is more specific than "Cyclophosphamide".
This graph shows the total number of publications written about "Cyclophosphamide" by people in this website by year, and whether "Cyclophosphamide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2001 | 1 | 3 | 4 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 2 | 3 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 3 | 3 |
| 2017 | 15 | 34 | 49 |
| 2018 | 17 | 31 | 48 |
| 2019 | 4 | 12 | 16 |
| 2020 | 1 | 5 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclophosphamide" by people in Profiles.
-
Anterior Scleritis Manifesting After Coronavirus Disease 2019: A Report of Two Cases. Cornea. 2021 Sep 01; 40(9):1204-1206.
-
Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma. Transfus Apher Sci. 2021 Oct; 60(5):103197.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
SARS-CoV-2 infection and recurrence of anti-glomerular basement disease: a case report. BMC Nephrol. 2021 02 27; 22(1):75.
-
COVID-19 reinfection in two children with cancer. Pediatr Hematol Oncol. 2021 05; 38(4):403-405.
-
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. J Med Case Rep. 2021 Feb 19; 15(1):90.
-
Surface contamination with nine antineoplastic drugs in 109 canadian centers; 10 years of a monitoring program. J Oncol Pharm Pract. 2022 Mar; 28(2):343-352.
-
Masquerading of COVID-19 Infection as Primary Mediastinal Large B-Cell Lymphoma Turk J Haematol. 2021 02 25; 38(1):77-78.
-
Mélange intéressante: COVID-19, autologous transplants and multiple sclerosis. Hematology. 2020 Dec; 25(1):320.
-
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience. Eur J Haematol. 2021 Mar; 106(3):340-345.